• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    $27.5M Bet On Block? Check Out These 3 Stocks Insiders Are Buying

    11/14/23 8:23:04 AM ET
    $AWR
    $JANX
    $SQ
    Water Supply
    Utilities
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AWR alert in real time by email

    Although U.S. stocks closed mixed on Monday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Block

    • The Trade: Block, Inc. (NYSE:SQ) 10% owner David Goel acquired a total of 540,646 shares an average price of $50.89. To acquire these shares, it cost around $27.52 million.
    • What’s Happening: Block reported better-than-expected third-quarter earnings.
    • What Block Does: Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2022, Square's payment volume was a little over $200 million.

    Janux Therapeutics

    • The Trade: Janux Therapeutics, Inc. (NASDAQ:JANX) 10% owner Avalon Bioventures I LP acquired a total of 849,854 shares at an average price of $5.87. To acquire these shares, it cost around $4.99 million.
    • What’s Happening: Janux Therapeutics posted a narrower-than-expected quarterly loss.
    • What Janux Therapeutics Does: Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.

    Don’t forget to check out our premarket coverage here

    American States Water

    • The Trade: American States Water Company (NYSE:AWR) Director Steven D Davis bought a total of 1,000 shares at an average price of $77.90. To acquire these shares, it cost around $77,899.
    • What’s Happening: American States Water posted downbeat quarterly earnings.
    • What American States Water Does: American States Water Co is water and utilities holding company based in California. The segments of the firm include water, electric, and contracted services.

     

    Check This Out: Fear Continues To Grip Markets Ahead Of Inflation Data

    Get the next $AWR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AWR
    $JANX
    $SQ

    CompanyDatePrice TargetRatingAnalyst
    Janux Therapeutics Inc.
    $JANX
    11/18/2025Peer Perform
    Wolfe Research
    Janux Therapeutics Inc.
    $JANX
    9/17/2025$47.00Overweight
    Barclays
    Janux Therapeutics Inc.
    $JANX
    9/10/2025$45.00Buy
    Stifel
    Janux Therapeutics Inc.
    $JANX
    9/10/2025$100.00Buy
    Truist
    Janux Therapeutics Inc.
    $JANX
    9/4/2025$72.00Buy
    Guggenheim
    Janux Therapeutics Inc.
    $JANX
    8/19/2025$42.00Overweight
    Piper Sandler
    Janux Therapeutics Inc.
    $JANX
    7/11/2025$65.00Outperform
    Raymond James
    American States Water Company
    $AWR
    5/8/2025$84.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $AWR
    $JANX
    $SQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharma

    2/26/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    American States Water Company Announces Fourth Quarter and Full Year 2025 Results

    $0.01 per share decrease in reported consolidated diluted EPS in the fourth quarter of 2025 compared to the fourth quarter of 2024 $0.18 per share increase on an adjusted basis after excluding the following items from the fourth quarter of 2024 reported results: a $0.13 per share one-time tax benefit as approved in the final decision in AWR's water utility general rate case $0.06 per share impact from retroactive rates related to the full year of 2023 and the nine months ended September 30, 2024 booked in the fourth quarter of 2024 after receiving the final decision in AWR's electric utility general rate case $0.20 per share increase in reported consolidated diluted EPS f

    2/18/26 4:30:00 PM ET
    $AWR
    Water Supply
    Utilities

    Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific engineered using the company's proprietary Adaptive Immune Response Modulator (ARM) platform. JANX011 is being developed for autoimmune diseases and is designed to enable deep and durable immune reset through targeted depletion of CD19-expressing B cells in blood and tissue. JANX011 is the first clinical candidate from Janux's proprietary ARM platform, which is designed to deliver sustained target B-cell depletion by harnes

    2/17/26 7:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AWR
    $JANX
    $SQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP of ASUS Connor Christopher H returned 3 shares to the company, was granted 2,801 shares and covered exercise/tax liability with 636 shares, increasing direct ownership by 55% to 6,103 units (SEC Form 4)

    4 - AMERICAN STATES WATER CO (0001056903) (Issuer)

    3/16/26 8:29:12 PM ET
    $AWR
    Water Supply
    Utilities

    Vice President Reg Affairs Pierotti Jon returned 3 shares to the company, covered exercise/tax liability with 462 shares and was granted 1,440 shares, increasing direct ownership by 34% to 3,699 units (SEC Form 4)

    4 - AMERICAN STATES WATER CO (0001056903) (Issuer)

    3/16/26 8:23:16 PM ET
    $AWR
    Water Supply
    Utilities

    President & CEO Sprowls Robert J returned 2 shares to the company, was granted 26,267 shares and covered exercise/tax liability with 10,429 shares, increasing direct ownership by 8% to 218,540 units (SEC Form 4)

    4 - AMERICAN STATES WATER CO (0001056903) (Issuer)

    3/16/26 8:22:31 PM ET
    $AWR
    Water Supply
    Utilities

    $AWR
    $JANX
    $SQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Janux Therapeutics

    Wolfe Research initiated coverage of Janux Therapeutics with a rating of Peer Perform

    11/18/25 8:24:27 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Janux Therapeutics with a new price target

    Barclays initiated coverage of Janux Therapeutics with a rating of Overweight and set a new price target of $47.00

    9/17/25 8:02:27 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Janux Therapeutics with a new price target

    Stifel initiated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $45.00

    9/10/25 4:00:02 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AWR
    $JANX
    $SQ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eichelberger Thomas A. bought $68,899 worth of shares (897 units at $76.81), increasing direct ownership by 12% to 8,467 units (SEC Form 4)

    4 - AMERICAN STATES WATER CO (0001056903) (Issuer)

    6/6/25 5:35:48 PM ET
    $AWR
    Water Supply
    Utilities

    Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    3/7/25 6:05:32 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP OF OPERATIONS Rowley Paul J returned 2 shares to the company and was granted 406 shares, decreasing direct ownership by 3% to 5,085 units (SEC Form 4)

    4 - AMERICAN STATES WATER CO (0001056903) (Issuer)

    2/11/25 8:00:25 PM ET
    $AWR
    Water Supply
    Utilities

    $AWR
    $JANX
    $SQ
    SEC Filings

    View All

    American States Water Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AMERICAN STATES WATER CO (0001056903) (Filer)

    3/13/26 4:31:50 PM ET
    $AWR
    Water Supply
    Utilities

    SEC Form S-8 filed by Janux Therapeutics Inc.

    S-8 - Janux Therapeutics, Inc. (0001817713) (Filer)

    2/26/26 4:47:06 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Janux Therapeutics Inc.

    10-K - Janux Therapeutics, Inc. (0001817713) (Filer)

    2/26/26 4:32:25 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AWR
    $JANX
    $SQ
    Leadership Updates

    Live Leadership Updates

    View All

    Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharma

    2/26/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

    Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities. Dr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-i

    1/26/26 7:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Butter Payments Names Sonali Sambhus as Chief Technology Officer to Support Rapid Expansion and Platform Innovation

    Seasoned technology leader joins as Butter looks to scale its machine learning-driven payments recovery platform Butter Payments, the most intelligent machine learning-powered payments recovery platform, today announced that it has strengthened its senior leadership team with the appointment of Sonali Sambhus as Chief Technology Officer (CTO). The appointment follows the recent additions of Sofya Pogreb as Chief Executive Officer and Charles Rosenblatt as Chief Commercial Officer. These leadership hires underscore Butter's ongoing momentum and investment in scaling technology, operations, and executive capabilities to meet growing demand across the subscription economy. Sonali Sambhus, C

    11/5/25 9:00:00 AM ET
    $AVDX
    $SQ
    Computer Software: Prepackaged Software
    Technology

    $AWR
    $JANX
    $SQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:24:38 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:17:06 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:01:49 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AWR
    $JANX
    $SQ
    Financials

    Live finance-specific insights

    View All

    American States Water Company Announces Fourth Quarter and Full Year 2025 Results

    $0.01 per share decrease in reported consolidated diluted EPS in the fourth quarter of 2025 compared to the fourth quarter of 2024 $0.18 per share increase on an adjusted basis after excluding the following items from the fourth quarter of 2024 reported results: a $0.13 per share one-time tax benefit as approved in the final decision in AWR's water utility general rate case $0.06 per share impact from retroactive rates related to the full year of 2023 and the nine months ended September 30, 2024 booked in the fourth quarter of 2024 after receiving the final decision in AWR's electric utility general rate case $0.20 per share increase in reported consolidated diluted EPS f

    2/18/26 4:30:00 PM ET
    $AWR
    Water Supply
    Utilities

    American States Water Company Announces Regular Common Dividends

    On February 10, 2026 the Board of Directors of American States Water Company (NYSE:AWR) approved a quarterly dividend of $0.5040 per share on the Common Shares of the company. This action marks the 359th consecutive dividend payment by the company. American States Water Company has paid dividends to shareholders every year since 1931, increasing the dividends received by shareholders each calendar year for 71 consecutive years, which places it in an exclusive group of companies on the New York Stock Exchange that have achieved that result. The company has grown its quarterly dividend rate at a compound annual growth rate (CAGR) of 8.5% over the last five years since the first quarter of 202

    2/11/26 4:57:00 PM ET
    $AWR
    Water Supply
    Utilities

    American States Water Company to Report Fourth Quarter and Full Year 2025 Results

    American States Water Company (NYSE:AWR) announced today that the company intends to release its fourth quarter and full year ended December 31, 2025 financial results after the market closes on Wednesday, February 18, 2026. Robert Sprowls, president and chief executive officer, and Eva Tang, senior vice president and chief financial officer, will host a conference call to discuss these results at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time) on Thursday, February 19. There will be a question-and-answer session as part of the call. Interested parties can listen to the live conference call and view accompanying slides on the internet at www.aswater.com. The call will be archived on the

    2/9/26 6:00:00 AM ET
    $AWR
    Water Supply
    Utilities